Fibrinolytic activity during orthotopic liver transplantation with and without aprotinin.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Transplantation

• Publication date

  1994-12-27

• Fields of study

  Medicine

• Identifiers
  PMID 7528949
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evolution of Urokinase-Type Plasminogen Activator (u-PA) and Tissue-Type Plasminogen Activator (t-PA) in Orthotopic Liver Transplantation (OLT)

  1993cited by this paper
• Diminished anticoagulant and fibrinolytic activity following liver transplantation.

  1992cited by this paper
• DECREASED PLATELET AGGREGATION AFTER REPERFUSION IN ORTHOTOPIC LIVER TRANSPLANTATION

  1992cited by this paper
• In Vitro Effect of Plasmin on Human Platelet Function in Plasma: Inhibition of Aggregation Caused by Fibrinogenolysis

  1992cited by this paper
• Intraoperative use of aprotinin (Trasylol) in orthotopic liver transplantation.

  1991cited by this paper
• Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis.

  1991cited by this paper
• The use of high dose aprotinin in liver transplantation: the influence on fibrinolysis and blood loss.

  1991cited by this paper
• Inhibition by aprotinin of tPA-mediated fibrinolysis during orthotopic liver transplantation.

  1990cited by this paper
• Intraoperative evolution of coagulation parameters and t-PA/PAI balance in orthotopic liver transplantation.

  1989cited by this paper
• Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol).

  1989cited by this paper
• Effect of aprotinin on intraoperative bleeding and fibrinolysis in liver transplantation.

  1989cited by this paper
• Hemostasis in liver transplantation.

  1989cited by this paper
• Coagulation changes following hepatic revascularization during liver transplantation.

  1989cited by this paper
• Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation.

  1989cited by this paper
• Fibrinolysis during liver transplantation in humans: role of tissue-type plasminogen activator.

  1988cited by this paper
• Aprotinin inhibits urokinase but not tissue-type plasminogen activator.

  1988cited by this paper
• Fibrin(ogen) peptide B beta 15-42 inhibits platelet aggregation and fibrinogen binding to activated platelets.

  1988cited by this paper
• The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor.

  1987cited by this paper
• Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage

  1986cited by this paper
• Urokinase Antigen in Plasma of Patients with Liver Cirrhosis and Hepatoma

  1985cited by this paper
• Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs.

  1983cited by this paper
• Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.

  1982cited by this paper

• Preventive correction of fibrinolysis with epsilon aminocaproic acid detected by thromboelastometry during liver transplantation

  2025cites this paper
• Trauma-induced coagulopathy

  2021cites this paper
• Primary hyperfibrinolysis: Facts and fancies.

  2018cites this paper
• Hyperfibrinolysis during liver transplantation is associated with bleeding

  2015cites this paper
• Mechanisms of Fibrinolysis and Basic Principles of Management

  2014cites this paper
• Monitoring Prohemostatic Treatment in Bleeding Patients

  2012cites this paper
• Methods to decrease blood loss and transfusion requirements for liver transplantation.

  2011cites this paper
• Hemostatic variation during perioperative period of orthotopic liver transplantation without venovenous bypass.

  2008cites this paper
• Fatal fibrinolysis during orthotopic liver transplantation in patients receiving solvent/detergent-treated plasma (Octaplas).

  2007cites this paper
• In Vitro and in Vivo Comparison of Antifibirinolytic Activity of Aprotinin and Tranexamic Acid Using a Thromboelastographic Method in Rabbits

  2005cites this paper
• Aprotinin inhibits local platelet trapping and improves tissue destruction in hepatic cryosurgery.

  2004cites this paper
• Fibrinolysis During Liver Transplantation Is Enhanced by Using Solvent/Detergent Virus-Inactivated Plasma (ESDEP®)

  2002cites this paper
• Coagulation: consultative hemostasis.

  2002cites this paper
• Haemostatic disorders during liver transplantation

  2001cites this paper
• Hyperfibrinolytic activity in hospitalized cirrhotic patients in a referral liver unit

  2000cites this paper
• Prothrombin complex concentrate substitution during liver transplantation.

  1999cites this paper
• Indications for therapeutic platelet transfusions.

  1998cites this paper
• Complement activation during major surgery: the effect of extracorporeal circuits and high-dose aprotinin.

  1998cites this paper
• Hemostasis and blood requirements in orthotopic liver transplantation with and without high-dose aprotinin.

  1998cites this paper
• The Blood Sparing Effect of Aprotinin Should Be Revisited

  1998cites this paper
• Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation

  1997cites this paper
• Contribution of cytokines to hyperfibrinolysis during orthotopic liver transplantation and effect of aprotinin

  1996cites this paper
• [Reduction of blood loss in orthotopic liver transplantation with the use of aprotinin].

  1996cites this paper
• Clinical evaluation of aprotinin

  1996cites this paper
• Hyperfibrinolysis.

  1996cites this paper
• Improved haemodynamic stability with administration of aprotinin during orthotopic liver transplantation.

  1995cites this paper
• A QUEDA DA PRESSÃO PORTAL APÓS DESVASCULARIZAÇÃO ESOFAGOGÁSTRICA E ESPLENECTOMIA INFLUENCIA A VARIAÇÃO DO CALIBRE DAS VARIZES E AS TAXAS DE RESSANGRAMENTO NA ESQUISTOSSOMOSE NO SEGUIMENTO EM LONGO PRAZO?

  year unknowncites this paper